Every Form 4 that Intelligent Bio Solutions Inc. (INBS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow INBS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INBS filings page.
Boyages Steven Constantine reported acquisition or exercise transactions in this Form 4 filing.
INTELLIGENT BIO SOLUTIONS INC. director Steven Constantine Boyages received a grant of 5,000 restricted shares of Common Stock on March 18, 2026 under the company’s 2019 Long Term Incentive Plan. These shares vest after 12 months and may be forfeited if vesting conditions are not met. Following this equity award, Boyages holds 5,031 common shares directly. All amounts are presented on a post–1-for-10 reverse stock split basis after the company’s December 15, 2025 reverse split.
Fraser Nicola Marion reported acquisition or exercise transactions in this Form 4 filing.
INTELLIGENT BIO SOLUTIONS INC. director Fraser Nicola Marion received an equity award rather than conducting an open‑market trade. On March 18, 2026, the company granted him 5,000 restricted shares of Common Stock under its 2019 Long Term Incentive Plan, at no cash purchase price.
The restricted shares vest based on time after 12 months and may be forfeited if vesting conditions are not met. Following this grant, Marion holds 5,000 shares of Common Stock directly, with all amounts presented on a post‑reverse‑split basis after the company’s prior reverse stock splits.
Sakiris Spiro Kevin reported acquisition or exercise transactions in this Form 4 filing.
INTELLIGENT BIO SOLUTIONS INC. Chief Financial Officer Kevin Sakiris received equity awards in the form of common stock. On March 18, 2026, he was granted 9,150 restricted shares that vest over 48 months and 21,350 restricted shares subject to both performance-based and time-based vesting, all under the 2019 Long Term Incentive Plan.
Following these compensation grants, Sakiris directly holds 33,981 shares of common stock and indirectly holds 1,911 shares through Anest Holdings Pty Ltd, as trustee of the S&T Sakiris Superannuation Fund. All share amounts are presented after a prior 1-for-10 reverse stock split.
Hurd Jonathan Scott reported acquisition or exercise transactions in this Form 4 filing.
INTELLIGENT BIO SOLUTIONS INC. director Jonathan Scott Hurd received a grant of 5,000 restricted shares of Common Stock on March 18, 2026 under the company’s 2019 Long Term Incentive Plan. The shares vest after 12 months and can be forfeited until vested. Following this award, he holds 5,006 shares directly, with all amounts presented after a 1-for-10 reverse stock split effected on December 15, 2025.
Isenberg Jason reported acquisition or exercise transactions in this Form 4 filing.
INTELLIGENT BIO SOLUTIONS INC. director Jason Isenberg reported an equity award of 5,000 shares of Common Stock. The shares were granted on March 18, 2026 under the company’s 2019 Long Term Incentive Plan at no cash cost and are his entire reported direct holding of 5,000 shares.
The 5,000 shares are restricted stock that vest after 12 months and are subject to forfeiture until they vest. All share amounts are presented on a post–1-for-10 reverse stock split basis reflecting the reverse split effected on December 15, 2025 and earlier reverse splits.
Simeonidis Harry reported acquisition or exercise transactions in this Form 4 filing.
Intelligent Bio Solutions Inc. granted Chief Executive Officer Harry Simeonidis new equity awards in the form of restricted common stock. On March 18, 2026, he received 9,150 restricted shares that vest over 48 months, and 21,350 additional restricted shares subject to both performance-based and time-based vesting conditions. These awards were issued at no cash cost under the company’s 2019 Long Term Incentive Plan and are subject to forfeiture until the vesting requirements are met. All share amounts reflect prior reverse stock splits, including a 1-for-10 split effective December 15, 2025.